Immune checkpoint blockade in patients with melanoma metastatic to the brain

Seminars in Oncology

Volumn 42, Issue 3, 2015, Pages 459-465

  Di Giacomo, Anna Maria ^a   Margolin, Kim ^b  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; FOTEMUSTINE; IPILIMUMAB; NIVOLUMAB; VEMURAFENIB; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; METASTATIC MELANOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; IMMUNOLOGY; MELANOMA; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CTLA-4 ANTIGEN; HUMANS; IMMUNOLOGIC FACTORS; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 84929170680     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.02.006     Document Type: Review

References (30)

1. R. Siegel, D. Naishadham, and L. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. K.E. Smedby, L. Brandt, M.L. Backlund, and P. Blomqvist Brain metastases admissions in Sweden between 1987 and 2006 Br J Cancer 101 2009 1919 1924
3. F. Vekeman, M. Cloutier, S. Yermakov, M.M. Amonkar, B. Arondekar, and M.S. Duh Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population Melanoma Res 2014 Jun 12
4. J.H. Sampson, J.H. Carter Jr, A.H. Friedman, and H.F. Seigler Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma J Neurosurgery 88 1 1998 11 20
5. N. Wasif, S.P. Bagaria, P. Ray, and D.L. Morton Does metastasectomy improve survival in patients with stage IV melanoma? A Cancer Registry analysis of outcomes J Surg Oncol 104 2 2011 111 115
6. U. Selek, E.L. Chang, and S.J. Hassebusch 3rd Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases Int J Radiat Oncol Biol Phys 59 2004 1097 1106
7. A. Hussain, P.D. Brown, S.L. Stafford, and B.E. Pollock Stereotactic radiosurgery for brainstem metastases: Survival, tumor control, and patient outcomes Int J Radiat Oncol Biol Phys 67 2007 521 524
8. K.M. Fife, M.H. Colman, and G.N. Stevens Determinants of outcome in melanoma patients with cerebral metastases J Clin Oncol 22 7 2004 1293 1300
9. M. Kocher, R. Soffietti, and U. Abacioglu Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study J Clin Oncol 29 2 2011 134 141
10. M.F. Avril, S. Aamdal, and J.J. Grob Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study J Clin Oncol 22 6 2004 1118 1125
11. Atkins MB, Sosman JA, Agarwala S, et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer. 2008;113(8):2139-45.
12. A. Hauschild, J.J. Grob, and L.V. Demidov Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 9839 2012 358 365
13. R. Kefford, M. Maio, and A. Arance Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, sigle-arm, phase2, multicentric study Pigment Cell Melanoma Res 26 2013 965
14. P.B. Chapman, A. Hauschild, and C. Robert BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 26 2011 2507 2516
15. G.V. Long, U. Trefzer, and M.A. Davies Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial Lancet Oncol 13 11 2012 1087 1095
16. L.M. Guirguis, J.C. Yang, and D.E. White Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases J Immunother 25 1 2002 82 87
17. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723
18. K. Margolin, M.S. Ernstoff, and O. Hamid Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Lancet Oncol 13 5 2012 459 465
19. D. Schadendorf, F.S. Hodi, and C. Robert Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma Eur J Cancer 49 3 suppl 2013 LB24
20. Heller KN, Pavlick AC, Hodi FS, et al. Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. J Clin Oncol. 2011;29 (suppl; abstr 8581).
21. J.D. Wolchok, A. Hoos, and S. O'Day Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
22. A.M. Di Giacomo, P.A. Ascierto, and L. Pilla A phase 2, open-label, single-arm study to investigate the combination of ipilimumab and fotemustine in patients with advanced melanoma: the NIBIT-M1 trial Lancet Oncol 13 2012 879 886
23. A.M. Di Giacomo, P.A. Ascierto, and P. Queirolo The Italian Network for Tumor Biotherapy (NIBIT)-M1 study: 2-years survival update for metastatic melanoma patients treated with ipilimumab in combination with fotemustine Eur J Cancer 49 2 suppl 2013 3740
24. M.A. Curran, W. Montalvo, H. Yagita, and J.P. Allison PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc Natl Acad Sci U S A 107 9 2010 4275 4280
25. J.D. Wolchok, H. Kluger, and M.K. Callahan Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2 2013 122 133
26. M. Maio, A.M. Di Giacomo, C. Robert, and A.M. Eggermont Update on the role of ipilimumab in melanoma and first data on new combination therapies Curr Opin Oncol 25 2013 166 172
27. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
28. J.M. Taube, A. Klein, and J.R. Brahmer Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin Cancer Res 20 19 2014 5064 5074
29. R. Kefford, A. Ribas, and O. Hamid Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475 J Clin Oncol 32 2014 5s (suppl; abstr 3005)
30. M.K. Callahan, C.E. Horak, and M.A. Curran Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab J Clin Oncol 2013 31 (suppl; abstr 3003)